Buy GLP-1 C + GLP-1 S

CagriSema is a fixed-ratio combination of cagrilintide—a long-acting amylin analogue—and semaglutide, the established GLP-1 receptor agonist. The combination exploits two distinct but mechanistically complementary hormonal axes to produce additive weight-loss effects that exceed either component alone. Semaglutide's GLP-1R-mediated mechanisms are well-established: hypothalamic NPY/AgRP suppression, POMC/CART upregulation, glucose-dependent insulin secretion, glucagon suppression, and gastric emptying delay. Cagrilintide operates through an entirely different receptor family, adding satiety and metabolic regulation through the amylin/calcitonin receptor pathway. Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta-cells in response to nutrient ingestion. Its cognate receptors—complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins 1, 2, or 3 (RAMP1, RAMP2, RAMP3)—are expressed prominently in the area postrema, nucleus tractus solitarius (NTS), lateral hypothalamus, and limbic structures. Native amylin's actions include slowing gastric emptying, suppressing post-meal glucagon secretion, and inducing satiety through brainstem NTS signalling. However, native amylin has a half-life of approximately 15 minutes, making pharmacological use impractical. Cagrilintide addresses this through an engineered sequence with multiple amino acid substitutions conferring DPP-4 resistance and a fatty acid chain providing albumin binding, extending the half-life to approximately 168 hours—enabling once-weekly dosing matched to semaglutide's administration schedule. The central mechanism of cagrilintide's satiety effect is particularly important for understanding CagriSema's superiority over semaglutide alone. While GLP-1R agonism suppresses appetite primarily through hypothalamic arcuate nucleus circuits (NPY/AgRP inhibition and POMC activation), amylin receptor activation signals through the area postrema and NTS—brainstem structures that process visceral and humoral satiety signals from the GI tract. These are anatomically distinct circuits that converge at the parabrachial nucleus and hypothalamic paraventricular nucleus to suppress meal size and frequency. The result is appetite suppression through two non-overlapping neural pathways that are additive rather than redundant. Peripheral contributions of cagrilintide include direct suppression of glucagon secretion from alpha-cells (complementing semaglutide's glucagon suppression via GLP-1R) and slowing of gastric emptying through a mechanism distinct from but additive to semaglutide's effect on antral contractility. Importantly, amylin receptor signalling in adipose tissue has been shown in preclinical models to enhance lipolysis via cAMP-mediated HSL activation, complementing the lipolytic effects of GLP-1R activation in white adipocytes. Additionally, cagrilintide appears to modulate the mesolimbic reward system through amylin receptors expressed in the ventral tegmental area, reducing food-reward salience through a pathway distinct from GLP-1R's dopaminergic modulation—further amplifying the hedonic appetite suppression that makes GLP-1-class drugs uniquely effective at reducing high-calorie food consumption.

The CagriSema 5 mg vial provides an introductory quantity for researchers exploring the amylin+GLP-1 dual-mechanism approach. Because CagriSema is a co-formulation, the dose ratios and escalation schedule differ from semaglutide monotherapy—researchers should reference the REDEFINE trial protocol structures when designing escalation schedules for research use. A conservative approach beginning at low fractions of the intended maintenance dose allows simultaneous establishment of tolerability for both the amylin and GLP-1 components, as the GI side-effect profiles of both are additive. The 5 mg vial is particularly appropriate for researchers who want to compare the amylin+GLP-1 dual mechanism against their prior semaglutide or tirzepatide experience. The qualitatively different satiety character of amylin receptor activation—described by many subjects as a more pronounced fullness signal rather than appetite pre-suppression—produces a distinct subjective experience from pure GLP-1R agonism. Observing and documenting this qualitative difference is a legitimate research objective that the 5 mg starter vial enables without requiring a large initial investment. From a quality assurance standpoint, CagriSema verification requires confirming both peptide components: HPLC and mass spectrometry should identify both the cagrilintide (approximately 4,740 Da) and semaglutide (4,113.58 Da) peaks, with combined purity documentation for the co-formulation. Cagrilintide's amide-modified C-terminus and fatty acid attachment create a distinct mass spectrometry fingerprint that serves as a primary authenticity marker. For the 5 mg format, ensure that the vial presentation and reconstitution instructions specify the co-formulation ratio, and that reconstituted solution concentration is sufficient for accurate dose measurement at the small volumes characteristic of introductory dose levels.

CagriSema's key differentiation from all GLP-1R agonists—including tirzepatide, which adds GIP-R co-agonism—is the amylin receptor pathway. Amylin receptor signalling engages brainstem satiety circuits (area postrema, NTS) that are anatomically and functionally distinct from the hypothalamic GLP-1R circuits engaged by semaglutide and the additional GIP-R circuits engaged by tirzepatide. This means that even in subjects who have experienced significant semaglutide tolerance or plateau effects over extended protocols, CagriSema's amylin component adds genuinely new satiety and metabolic regulation that these subjects have not previously been exposed to. Against tirzepatide's SURMOUNT-1 outcome (20.9%), CagriSema's REDEFINE-1 preliminary data (~22.7%) suggest modest incremental superiority, though head-to-head trials are needed for definitive comparison. The mechanistic distinction is important: tirzepatide adds lipolytic enhancement via adipose GIP-R activation, while CagriSema adds brainstem satiety circuit engagement via amylin receptor activation. These are different mechanisms producing numerically similar outcomes, and individual response may vary based on which pathway is the limiting factor for a given subject. For researchers who have characterised their response to GLP-1+GIP co-agonism and wish to explore the amylin alternative, CagriSema represents the scientifically rational next step.